Economic evaluation of gene-replacement therapies: abstract highlights from day 2 of ISPOR Europe 2019

Written by The Evidence Base
Cardiopulmonary and vascular Decision science Events coverage Health economics ISPOR Medical devices, pharmaceuticals and vaccines Methodology News Oncology and hematology Outcomes research Rare diseases and orphan drugs

As part of our continuous coverage of the ISPOR Europe 2019 (2—6 November; Copenhagen, Denmark) meeting, we bring you our abstract highlights from the second day of the conference: gene therapies, acute coronary syndrome and more! Abstract highlights: Economic evaluation of gene-replacement therapies: challenges and potential methodological solutions Acute coronary syndrome; resource use and costs A budget-impact analysis of somatostatin analogues for the treatment of gastroenteropancreatic cancer and acromegaly Economic evaluation of gene-replacement therapies: challenges and potential methodological solutions Researchers from Creativ-Ceutical (Luxembourg) and Aix-Marseille University (Marseille, France) have conducted a literature review, alongside interviews with eight, leading health economists,...

To view this content, please register now for access

It's completely free